

# GOPEN ACCESS

**Citation:** Lim SH, Lee S, Lee YB, Lee CH, Lee JW, Lee S-H, et al. (2022) Increased prevalence of transfusion-transmitted diseases among people with tattoos: A systematic review and metaanalysis. PLoS ONE 17(1): e0262990. https://doi. org/10.1371/journal.pone.0262990

Editor: Maria R. Khan, New York University School of Medicine, UNITED STATES

Received: February 20, 2021

Accepted: January 10, 2022

Published: January 27, 2022

**Peer Review History:** PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0262990

**Copyright:** © 2022 Lim et al. This is an open access article distributed under the terms of the <u>Creative</u> Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its <u>Supporting Information</u> files.

**RESEARCH ARTICLE** 

Increased prevalence of transfusiontransmitted diseases among people with tattoos: A systematic review and metaanalysis

Sung Ha Lim<sup>1</sup><sup>©</sup>, Solam Lee<sup>1,2</sup><sup>©</sup>, Young Bin Lee<sup>1</sup>, Chung Hyeok Lee<sup>1</sup>, Jong Won Lee<sup>1</sup>, Sang-Hoon Lee<sup>1</sup>, Ju Yeong Lee<sup>1</sup>, Joung Soo Kim<sup>3</sup>, Mi Youn Park<sup>4</sup>, Sang Baek Koh<sup>2</sup>, Eung Ho Choi<sup>1</sup>\*

Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea,
Department of Preventive Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea,
Department of Dermatology, Hanyang University College of Medicine, Guri, Republic of Korea,
Department of Dermatology, National Medical Center, Seoul, Republic of Korea

So These authors contributed equally to this work.

\* choieh@yonsei.ac.kr

## Abstract

Whether having a tattoo increases the risk of transfusion-transmitted diseases (TTDs) is controversial. Although a few studies have suggested a strong association between having tattoos and TTDs, other studies have not shown the significance of the association. In addition, previous studies mainly focused only on hepatitis C viral infections. The objective of our study was to identify the prevalence and risk of TTDs in people with tattoos as compared with the non-tattooed population. A systematic review of the studies published before January 22, 2021, was performed using the Pubmed, Embase, and Web of Science databases. Observational studies on hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and syphilis infections in people with and without tattoos were included. Studies that reported disease status without serological confirmation were excluded. A total of 121 studies were quantitatively analyzed. HCV (odds ratio [OR], 2.37; 95% confidence interval [CI], 2.04–2.76), HBV (OR, 1.55; 95% CI, 1.31–1.83), and HIV infections (OR, 3.55; 95% CI, 2.34-5.39) were more prevalent in the tattooed population. In subgroup analyses, the prevalence of HCV infection was significantly elevated in the general population, hospital patient, blood donor, intravenous (IV) drug user, and prisoner groups. IV drug users and prisoners showed high prevalence rates of HBV infection. The prevalence of HIV infection was significantly increased in the general population and prisoner groups. Having a tattoo is associated with an increased prevalence of TTDs. Our approach clarifies in-depth and supports a guideline for TTD screening in the tattooed population.

**Funding:** EHC was supported by the Korean Dermatology Research Foundation (2019). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

## Introduction

Tattoos are becoming rapidly popular among young people, as they have become recognized as a means of self-expression [1, 2]. According to a worldwide survey conducted in 2019 [3], the prevalence of tattoos was reported to range from 12.2% to 31.5% depending on the region. A population-based study found that more than one-third of young adults in the United States have tattoos [4]. Tattooing is an invasive procedure that involves the injection of pigmentary particles into the dermal layer of the skin through repeated skin punctures. Therefore, it poses a potential risk of infection by diverse microorganisms if the ink or instrument used for tattooing is reused without a proper disinfection procedure.

Transfusion-transmitted diseases (TTDs) are blood-borne infectious diseases that include hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), and syphilis infections [5, 6]. In 2016, 1.90 million patients with HCV infection in the United States were identified, but only 49.8% of them knew about their disease status [7]. Moreover, 1.10 million patients with HIV infection were also reported, but one-seventh of them were not aware of their infection [8]. The most important risk factor for the transmission of TTDs has been known as sharing needles and equipment for drug use.

However, whether having tattoos increases the risk of transmission of TTDs is still controversial. A few studies have suggested a strong association between having tattoos and TTDs [9-13]; however, other studies have not shown the significance of the association [14-16]. Some systematic reviews and meta-analyses [17-20] have reported that tattooing in certain groups could increase the risk of HCV transmission. However, previous studies were mainly limited to HCV infection, and studies performing comprehensive evidence syntheses, including other TTDs, using a uniform methodology are currently lacking. Therefore, the purpose of this systematic review and meta-analysis was to investigate the prevalence and risk of HCV, HBV, HIV, and syphilis infections in people with tattoos as compared with the non-tattooed population.

## Materials and methods

### Search strategy

We performed a comprehensive literature search in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guidelines. The Pubmed, Embase, and Web of Science databases were searched. One of the main reviewers (S. L.) performed the literature search, using the following search keywords: "tattoo\*," "HIV," "AIDS," "immunodef\*," "hepatitis," "HCV," "HBV," "HBsAg," "syphilis," "VDRL," "TPHA," "treponema\*," "transfu\*," "blood\*," and "infect\*." The detailed search strategies for the databases are summarized in S1 File. The literature search included the studies published until January 22, 2021. Articles written in English and Korean were included because of the authors' proficiencies in these languages.

## Study selection

Four main reviewers (S.L., S.H.L., Y.B.L., and C.H.L.) evaluated the titles and abstracts of the retrieved studies. All individual studies were independently reviewed by at least two reviewers. Any disagreements between the reviewers regarding the suitability of the studies were discussed with two other reviewers (J.W.L. and S.H.L.) and resolved by consensus. All the observational studies on HCV, HBV, HIV, and syphilis infections that investigated both individuals with and without tattoos were included. Meanwhile, the following studies were excluded: 1) non-research articles, 2) studies that reported disease status without serological confirmation

(e.g., self-response questionnaire), 3) studies that only investigated either subjects with or without tattoos (non-comparability), and 4) studies with insufficient sample sizes (n < 20).

#### Data extraction and quality assessment

Data regarding publication details, study setting, population demographics, and serological findings were extracted from each study. The number of events (positive in serology) and total observations for HCV, HBV, HIV, and syphilis infections in both the tattooed and non-tattooed groups were extracted from case-control, cross-sectional, and case-series studies. For cohort and any other studies that performed a time-to-outcome analysis, the hazard ratio (HR) for each finding was directly extracted. The adapted Newcastle-Ottawa scale for assessing the quality of observational studies was used for the assessment of the analyzed studies [21]. Finally, the articles with adequate quality (score  $\geq$  3) were included in the quantitative meta-analysis.

#### Data synthesis and outcomes

For case-control, cross-sectional, and case-series studies, we calculated the odds ratio (OR) as a summary statistical variable for comparing the prevalence of TTDs in the tattooed and nontattooed populations. The HRs obtained from each study were to be meta-analyzed with timeto-outcome analysis. A random-effects model was used in the meta-analysis because a significant heterogeneity between the included studies was expected. The  $I^2$  statistics was used to estimate and quantify the heterogeneity between the studies. Subgroup analyses (general population, hospital patients, blood donors, intravenous (IV) drug users, and prisoners) for the study populations ( $\geq$ 3 studies) were performed to address the heterogeneity. General population were those who were included population-based (community) studies. In contrast to other subgroups, which are within characteristic environments that favor an increased prevalence of TTDs in the tattooed population, we thought it is worth estimating the prevalence in a sample which can be approximated to the general population. Egger's linear regression test was performed to evaluate publication bias. The trim-and-fill method was used to adjust the summary statistics when a significant publication bias was detected. The analysis was performed using R version 3.5.0 (R Foundation for Statistical Computing). A p value of <0.05 was considered statistically significant.


### Code and data availability


The final datasheet for extraction, program code used for the quantitative synthesis, and forest plots for individual analyses can be accessed at our public repository at <a href="https://doi.org/10.17632/cgpp4fzxhd.1">https://doi.org/10.17632/cgpp4fzxhd.1</a>.

### Results

### Study selection and characteristics

The PRISMA flow diagram is presented in Fig 1. Among the 2,030 publications screened, 798 full-text articles were assessed for eligibility. A total of 121 studies were quantitatively analyzed (Tables 1 and <u>S1</u> and <u>S2</u>). However, none was a cohort study that included a time-to-outcome analysis. The adapted Newcastle-Ottawa scale for assessing the quality of the included cross-sectional studies is presented in <u>S3 Table</u>. The summary statistics for the HCV, HBV, HIV, and syphilis infections in the tattooed group as compared with the non-tattooed group are shown in Fig 2.





https://doi.org/10.1371/journal.pone.0262990.g001

## **HCV** infection

A total of 86 studies that reported HCV serostatus were meta-analyzed (Fig 2A). HCV infection was significantly more prevalent in the tattooed group than in the non-tattooed group (meta-analyzed OR, 2.89; 95% confidence interval [CI], 2.48–3.37). However, a possible publication bias among the studies that reported HCV serostatus was suggested by the funnel plot (Fig 3A) and Egger's test (p = 0.01). Nevertheless, HCV infection was still more prevalent in the tattooed group even after adjustment for publication bias using the trim-and-fill method (adjusted OR, 2.37; 95% CI, 2.04–2.76). Likewise, all the subgroup analyses revealed a statistically significant increase in the prevalence of HCV infection in the tattooed group as compared with the non-tattooed group (Table 2).

### **HBV** infection

In total, 48 studies that reported HBV serostatus were meta-analyzed (Fig 2B). HBV infection was significantly more prevalent in the tattooed group than in the non-tattooed group (meta-analyzed OR, 1.55; 95% CI, 1.31–1.83).

Variables	N	%	Variables		N	%
Countries	121	100	Study populatio	Study populations		100
Iran	23	19.0	General populati	General population		31.0
Brazil	13	10.7	Hospital patients		24	20.7
U.S.A.	12	9.9	Blood donors		6	5.2
India	9	7.4	Intravenous drug users		25	21.6
Australia	6	5.0	Prisoners	Prisoners		21.6
Mexico	5	4.1	Disease			
Taiwan	5	4.1	HCV		86	
Thailand	5	4.1		Anti-HCV	81	94.2
Nigeria	4	3.3		HCV-RNA	5	5.8
Pakistan	3	2.5	HBV		48	
Bosnia	2	1.7		HBsAg	38	79.2
Canada	2	1.7		Anti-HBc	6	12.5
Ethiopia	2	1.7		HBV-DNA	3	6.3
France	2	1.7		HBs Ab	1	2.1
Italy	2	1.7	HIV		20	
Spain	2	1.7		Anti-HIV	20	100
Others	24	19.8	Syphilis		3	
				RPR, VDRL test	3	100

#### Table 1. Summary of the included studies.

Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus; RPR, rapid plasma regain; VDRL, venereal disease research laboratory.

https://doi.org/10.1371/journal.pone.0262990.t001

Similarly, all the subgroup analyses revealed an increased prevalence of HBV infection in the tattooed group as compared with the non-tattooed group (Table 2). However, a possible publication bias was suggested for the studies that reported HBV serostatus among general population subgroup (Egger's test, p = 0.04), hospital patients (Egger's test, p = 0.04), and IV drug users (Egger's test, p = 0.02). Nevertheless, a tendency toward increased prevalence of HBV infection was observed among general population subgroup (adjusted OR, 1.41; 95% CI, 0.98–2.03) and IV drug users (adjusted OR, 1.46; 95% CI, 1.16–1.83).

#### HIV infection and syphilis

A total of 20 studies that reported HIV serostatus were meta-analyzed (Fig 2C). HIV infection was markedly more prevalent in the tattooed group than in the non-tattooed group (meta-analyzed OR, 3.55; 95% CI, 2.34–5.39). However, only the general population (meta-analyzed OR, 2.73; 95% CI, 1.35–5.54) and the prisoners (meta-analyzed OR, 4.29; 95% CI, 3.32–5.54) showed a statistical significance in the subsequent subgroup analyses (Table 2). For syphilis infection, only 3 studies were identified (Fig 2D). Although syphilis tended to be more prevalent in the tattooed group, it did not reach statistical significance (OR, 1.55; 95% CI, 0.76–3.17). In addition, a subgroup analysis for the study population could not be performed because of the insufficient number of studies.

## Discussion

Our systematic review investigated the association between having a tattoo and TTDs. Previous systematic reviews reported a possible positive association between tattooing and each TTD [18]. For HCV infection, two previous studies reported positive associations with having

(A)		HCV		(B)		HBV	
	Study	OR 95%-CI	Odds Ratio		Study	OR 95%-CI	Odds Ratio
	Moradi et al, 2020	1.52 [1.20; 1.93]			Belay et al, 2020	4.47 [2.98; 6.72]	
	Okafor et al, 2020	0.67 [0.27; 1.63]			Moradi et al, 2020 Azarkar et al, 2019	0.96 [0.47; 1.97] 3.32 [0.87; 12.61]	
	Hagan et al, 2019 Mohd Suan et al, 2019	3.05 [2.41; 3.88] 6.92 [2.65; 18.10]			Moradi et al, 2019 Shojaee et al, 2019	1.13 [0.85; 1.50] 0.43 [0.34; 0.54]	= Ť
	Moradi et al, 2019	3.46 [2.83; 4.23]			Drazilova et al, 2018	1.90 [1.11; 3.26]	
	Bielen et al, 2018 Moradi et al, 2018	2.81 [1.38; 5.73] 2.23 [1.85; 2.68]			Moradi et al, 2018 Tabasi et al, 2018	1.04 [0.74; 1.46] 1.95 [0.81; 4.73]	
	Wasitthankasem et al, 2018	3.22 [2.48; 4.18]			Kebede et al, 2017	0.79 [0.09; 6.69]	
	Tabasi et al, 2018 Silva et al, 2018	4.80 [2.10; 10.98] 3.76 [2.30; 6.15]			Bhate et al, 2016 Melo et al, 2015	5.12 [1.44; 18.20] 1.92 [0.73; 5.06]	
	Poulin et al, 2018	1.45 [1.06; 1.96]	-		Dwibedi et al, 2014 Keyvani et al, 2014	1.75 [1.29; 2.39] 2.13 [0.77; 5.93]	
	Belaunzaran-Zamudio et al, 2017 Hodzic et al, 2017	4.19 [2.50; 7.02] 2.10 [0.67; 6.58]			Shittu et al, 2014	1.11 [0.37; 3.33]	
	Kebede et al, 2017	2.20 [0.22; 22.20]			Calleja-Panero et al, 2013 Gheorghe et al, 2013	2.05 [0.96; 4.37] 1.68 [1.23; 2.29]	2 2 2
	Wasitthankasem et al, 2017	4.37 [3.39; 5.64]	-		Matos et al, 2013 Zhang et al, 2013	8.42 [2.02; 35.01] 1.19 [1.01; 1.41]	
	Silverman-Retana et al, 2017 Rosinska et al, 2017	2.77 [1.74; 4.43] 2.33 [1.30; 4.20]			Ghadir et al, 2012	3.08 [1.29; 7.35]	10 mm
	Akhtar et al, 2016	2.70 [1.45; 5.02]			Abedi et al, 2011 Fathimoghaddam et al, 2011	3.41 [1.66; 7.01] 2.90 [0.66; 12.69]	
	Ba-Essa et al, 2016 Mac Donald-Ottevanger et al, 2016	6.67 [1.43; 31.02] 1.62 [0.66; 4.00]			Jahangirnezhad et al, 2011 Urbanus et al, 2011	26.51 [3.55; 197.71] 2.75 [0.36; 21.09]	
	Skocibusic et al, 2016	0.60 [0.29; 1.24]			Lin et al, 2010	1.74 [1.58; 1.92]	
	Moezzi et al, 2015 Nakhla et al, 2015	4.68 [2.07; 10.59] 1.53 [1.13; 2.09]			Meffre et al, 2010 Miller et al, 2009	1.09 [0.86; 1.37] 1.32 [0.84; 2.06]	<u>1</u>
	Oliveira et al, 2015	3.54 [1.19; 10.56]			Tavakkoli et al, 2008	0.81 [0.32; 2.02]	
	Pacheco et al, 2014 Wenger et al, 2014	9.48 [3.81; 23.61] 4.19 [2.23; 7.87]			Butler et al, 2007 Lai et al, 2007	1.69 [1.02; 2.78] 0.67 [0.35; 1.28]	
	Calleja-Panero et al, 2013	2.74 [1.26; 5.98]			Shi et al, 2007 Pourahmad et al, 2007	1.37 [0.98; 1.93] 1.85 [1.00; 3.43]	
	Matos et al, 2013 Oliveira-Filho et al, 2013	1.78 [0.22; 14.41] 9.10 [5.09; 16.26]			Hwang et al, 2006	0.95 [0.72; 1.27]	+
	Azevedo et al, 2012	2.33 [0.24; 22.66]			Liao et al, 2006 Mendez-Sanchez et al, 2006	1.49 [0.78; 2.84] 9.78 [1.68; 56.96]	
	Hermanstyne et al, 2012 Liakina et al, 2012	2.08 [1.20; 3.61] 4.84 [1.96; 11.95]			Babudieri et al, 2005 Nishioka et al, 2003	1.15 [0.89; 1.48] 2.90 [1.51; 5.57]	tille til
	Nokhodian et al, 2012	2.03 [1.43; 2.88]	-		Ozsoy et al, 2003	1.17 [0.15; 9.00]	
	Strehlow et al, 2012 Souto et al, 2012	3.11 [1.99; 4.86] 4.16 [2.83; 6.11]			Gani et al, 2002 Gyarmathy et al, 2002	0.60 [0.13; 2.75] 1.15 [0.65; 2.03]	
	Satti et al, 2012	0.98 [0.52; 1.85]			Risbud et al, 2002 Samuel et al, 2001	2.56 [1.77; 3.71] 1.69 [1.22; 2.35]	
	Rodrigues Neto et al, 2012 Nurutdinova et al, 2011	3.35 [1.03; 10.91] 1.60 [1.10; 2.32]			Coppola et al, 2000	1.38 [0.90; 2.12]	
	Viitanen et al, 2011	3.86 [2.49; 5.97]			Silverman et al, 2000 Wada et al, 1999	3.03 [0.12; 75.19] 1.59 [0.14; 18.31]	
	Pompilio et al, 2011 Mahfoud et al, 2010	2.36 [1.05; 5.31] 12.73 [0.73; 221.08]			Sebastian et al, 1992 Tibbs, 1987	2.45 [1.35; 4.45] 0.46 [0.32; 0.67]	+
	Meffre et al, 2010	3.32 [2.11; 5.23]	6 		Hull et al, 1985	2.23 [1.34; 3.70]	
	Khin et al, 2010 Teutsch et al, 2010	1.03 [0.38; 2.77] 1.76 [1.01; 3.08]			Olumide et al, 1976	0.35 [0.05; 2.68]	
	Coelho et al, 2009	8.18 [3.23; 20.74]			Fixed effect model Random effects model	1.39 [1.32; 1.46] 1.55 [1.31; 1.83]	•
	Felippe et al, 2009 Kheirandish et al, 2009	9.27 [3.87; 22.22] 2.42 [1.31; 4.47]			Heterogeneity: $I^2 = 84\%$ , $\tau^2 = 0.2093$ , p		0.01 0.1 1 10 100
	Miller et al, 2009	1.24 [0.79; 1.95]					HBV
	Zakizad et al, 2009 Vickery et al, 2009	5.79 [3.21; 10.43] 3.73 [2.32; 5.99]		(C)		HIV	
	Chelleng et al, 2008 Macias et al, 2008	1.72 [0.83; 3.58] 3.31 [1.29; 8.49]		(0)			
	Sayad et al, 2008	7.66 [2.74; 21.36]			Study	OR 95%-CI	Odds Ratio
	Butler et al, 2007 Lai et al, 2007	2.28 [1.50; 3.46] 2.87 [1.48; 5.59]	<u>+</u>				
	Lim et al, 2007	4.18 [1.24; 14.10]			Etemad et al, 2020 Patil et al, 2020	4.51 [1.74; 11.70] 2.74 [0.72; 10.33]	
	Mohtasham Amiri et al, 2007 Neumeister et al, 2007	2.07 [1.42; 3.03] 3.51 [1.28; 9.57]			Haider et al, 2019 Kebede et al, 2017	7.67 [1.71; 34.40] 7.00 [0.93; 52.67]	
	Nguyen et al, 2007	9.83 [1.90; 50.95]			Javadi et al, 2013	4.25 [0.49; 36.65]	
	Zamani et al, 2007 Shi et al, 2007	1.55 [0.88; 2.73] 5.06 [1.83; 14.00]			Matos et al, 2013 Navadeh et al, 2013	8.29 [1.47; 46.69] 3.53 [2.19; 5.70]	
	Pourahmad et al, 2007	2.95 [2.35; 3.71]	1		Dandona et al, 2008 Shi et al, 2007	3.24 [2.10; 5.01]	4
	Hwang et al, 2006 Khaja et al, 2006	1.11 [0.58; 2.10] 0.12 [0.03; 0.51]			Pourahmad et al, 2007 Jombo et al, 2006	4.03 [2.41; 6.75] 0.75 [0.30; 1.86]	
	Liao et al, 2006	2.18 [1.02; 4.69]			Babudieri et al, 2005	3.68 [2.13; 6.37]	
	Mendez-Sanchez et al, 2006 Sahajian et al, 2006	1.32 [0.07; 24.16] 2.99 [1.33; 6.72]			Panda et al, 2005 Nishioka et al, 2003	35.02 [14.00; 87.58] 29.65 [ 3.98; 220.57]	
	Reyes et al, 2006	5.34 [2.54; 11.21]			Thaisri et al, 2003 Gyarmathy et al, 2002	6.47 [3.81; 11.00] 0.54 [0.21; 1.38]	
	Alvarado-Esquivel et al, 2005 Babudieri et al, 2005	41.60 [5.38; 321.54] 2.97 [2.27; 3.89]			Entz et al, 2000	2.19 [1.48; 3.24]	-
	Dominitz et al, 2005	5.72 [3.21; 10.19]			Wada et al, 1999 Sawanpanyalert et al, 1996	1.85 [0.24; 14.11]	
	Howe et al, 2005 Nishioka et al, 2003	1.24 [0.56; 2.73] 17.41 [4.10; 73.90]			Rodrigues et al, 1995	1.45 [1.19; 1.77]	*
	Gani et al, 2002	13.18 [1.75; 99.13]			Fixed effect model	2.59 [2.29; 2.93]	•
	Gyarmathy et al, 2002 Haley et al, 2001	2.20 [1.10; 4.41] 7.81 [4.09; 14.92]			Random effects model Heterogeneity: $I^2 = 85\%$ , $\tau^2 = 0.5438$ , p	<b>3.55 [2.34; 5.39]</b>	
	Muller et al, 2001	5.08 [2.89; 8.93]	-				0.01 0.1 1 10 100 HIV
	Samuel et al, 2001 Roy et al, 2001	0.18 [0.13; 0.26] 4.01 [1.96; 8.19]	· · · · · · · · · · · · · · · · · · ·	(= )			
	Coppola et al, 2000	10.17 [5.78; 17.90]	-	(D)		Syphilis	
	Silverman et al, 2000 Lucas et al, 1999	2.43 [0.61; 9.65] 1.61 [0.80; 3.23]					
	Wada et al, 1999 Sawanpanyalert et al, 1996	5.28 [1.98; 14.09] 5.10 [1.14; 22.79]			Study OR	95%-CI	Odds Ratio
	Holsen et al, 1993	8.25 [2.80; 24.30]				[0.42; 2.95]	
	Ko et al, 1992	5.93 [1.60; 21.95]			Shi et al, 2007 Nishioka et al, 2003 2.30	[0.79; 6.67]	
	Fixed effect model	2.48 [2.35; 2.61]			Fixed effect model 1.58	[0.80; 3.14]	
	Random effects model Heterogeneity: $I^2 = 85\%$ , $\tau^2 = 0.3651$ , $p < 0.1$	2.89 [2.48; 3.37]	r			[0.76; 3.17]	
	σ ,		0.01 0.1 1 10 100				0.2 0.5 1 2 5
			HCV				Syphilis

**Fig 2.** Forest plots summarizing the meta-analysis. Forest plots of the meta-analysis. (A) HCV, (B) HBV, (C) HIV, and (D) Syphilis. Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus.

https://doi.org/10.1371/journal.pone.0262990.g002




Fig 3. Funnel plots for the assessment of publication bias. Funnel plots of the meta-analyses. (A) HCV, (B) HBV, and (C) HIV. Abbreviations: HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus.

https://doi.org/10.1371/journal.pone.0262990.g003

a tattoo, with pooled ORs of 2.74 (95% CI, 2.38–3.15) [19] and 2.79 (95% CI, 2.46–3.18) [17], respectively. In addition, HIV infection has been reported to be more prevalent in tattooed subjects [22]. However, a literature search for syphilis in tattooed subjects is lacking.

Disease	Subgroup <sup>a</sup>	No. of studies	No. of tattoo users	No. of controls	OR (95% CI)	$I^2$	Egger's test
HCV	(All)	86	30665	171103	2.89 (2.48-3.37)	85%	0.01
					<sup>b</sup> 2.37 (2.04–2.76)		
	General population	18	5812	31492	2.94 (2.32-3.73)	70%	0.43
	Hospital patients	16	4919	46114	4.27 (3.21-5.68)	53%	0.71
	Blood donors	5	812	67477	3.27 (1.48-7.21)	77%	0.85
	Intravenous drug users	22	3733	3501	2.37 (1.54-3.67)	92%	0.08
	Prisoners	19	12890	13275	2.99 (2.50-3.56)	66%	0.12
HBV	(All)	48	25886	91495	1.55 (1.31-1.83)	84%	0.19
	General population	16	5185	43828	2.04 (1.42-2.93)	85%	0.04
					<sup>b</sup> 1.41 (0.98–2.03)		
	Hospital patients	12	2475	27141	1.97 (1.15-3.37)	91%	0.04
					<sup>b</sup> 0.91 (0.54–1.53)		
	Intravenous drug users	6	1276	1166	1.40 (1.13–1.74)	0%	0.02
					<sup>b</sup> 1.46 (1.16–1.83)		
	Prisoners	9	14336	13923	1.35 (1.07-1.70)	74%	0.15
HIV	(All)	20	6917	17873	3.55 (2.34-5.39)	85%	0.10
	General population	5	1010	6976	2.73 (1.35-5.54)	64%	0.71
	Hospital patients	3	874	2548	5.71 (0.87-37.47)	86%	0.20
	Intravenous drug users	3	490	581	4.33 (0.21-88.3)	95%	0.67
	Prisoners	5	3712	4069	4.29 (3.32-5.54)	0%	0.21
Syphilis	(All)	3	692	2203	1.55 (0.76-3.17)	0%	-

Table 2. Meta-analyzed estimates of the prevalence rates of transfusion-transmitted diseases among subjects with tattoos.

Abbreviations: OR, odds ratio; 95% CI, 95% confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus; HIV, human immunodeficiency virus

<sup>a</sup>Subgroup analyses were performed when three or more studies were available for each subgroup.

<sup>b</sup>Adjusted OR with the trim-and-fill method for possible publication bias.

https://doi.org/10.1371/journal.pone.0262990.t002

In line with previous studies, the results of our study show that the likelihood of having TTDs (HCV, HBV, and HIV infections) among subjects with tattoos is higher than that of the non-tattooed population. This result is consistent with the known knowledge that sharing needles, syringes, or other equipment to inject drugs that may have come in contact with another person's blood is a high-risk factor for TTDs [23-26]. This result was unchanged even after additional adjustment for possible publication bias. Furthermore, we categorized the included studies into TTD subgroups in the general population, hospital patient, blood donor, IV drug user, and prisoner groups to elucidate the specific factors that may have been involved in the spread of TTDs. For HCV infection, all subgroups showed a significant increase in disease transmission rate among the patients with tattoos. However, for HBV infection, only the IV drug user and prisoner groups showed a significant increase in disease incidence rate in the subjects with tattoos after adjusting for publication bias. The prevalence of HIV infection was significantly increased in the general population and prisoner subgroups, although the hospital patients and IV drug users did not show significant differences between the tattooed and nontattooed groups. This result could be derived from the small number of studies and the included subjects in each subgroup. In the subgroup analyses, the HCV prevalence rate was highest in the hospital subgroup. Although it was statistically not significant, the HIV infection rate was also highest in the hospital subgroup. This may be attributable to the distinguishable characteristic of hospital patients of having awareness of or concern about their illness or symptoms. The IV drug user and prisoner subgroups showed marked increases in the prevalence rates of HCV, HBV, and HIV infections in the tattooed group as compared with the non-tattooed group. Long et al. [27] reported in 2011 that the proportion of prison entrants with tattoos increased with the increasing time spent in the Irish prison over 10 years. They also reported that prisoners who had spent >3 of 10 years were significantly more likely to test positive for HIV antibodies. Adjei et al. [28] also reported that the prevalence rates of HCV, HBV, and HIV infections among prison inmates independently correlated with IV drug use and being incarcerated for > 36 months. One study proposed that prisoners tended to be involved in incautious IV drug use because they are exposed to risk behaviors and peer pressures without the concept of sanitation [29]. These results further infer that subjects with tattoos may be associated with increased exposure to unhygienic IV drug use, which leads to the spread of TTDs. Furthermore, a study showed that opioid-substituted treatment in prison led to a reduction in IV injection-associated HIV risk behaviors such as injecting drugs or sharing needles [30]. Overall, although our study did not differentiate prison inmates with tattoos before and after the incarceration, the results imply that prisoners and IV drug users who might have been exposed to an unsafe environment during tattooing could contribute to the increased prevalence of TTDs.

The association of having a tattoo with HBV infection, although some data indicated statistical significance, was not evident compared to the patients with HCV and HIV infections. We assumed that this tendency is attributed to the availability of vaccines for HBV, unlike HCV and HIV, for which vaccines are not yet available. Gahrton et al. [31] reported that the proportion of prisoners in Stockholm who had received HBV vaccination was estimated to be 40.6%. Vaccination prior to the infection may have played a protective role and decreased the overall morbidity of HBV infection. Information on each subject's vaccination history could be useful for evaluating the independent effect of vaccination in future analysis. Moreover, the included studies were predominantly from countries with low HBV prevalence rates [32]. For instance, the largest number of papers and subjects included for HBV infection analysis were from Iran, where the HBV prevalence was <2% [32]. Moreover, among all the included subjects, 59% were from countries with low HBV prevalence rates (<2%), which might have led to reduced statistical power. For syphilis infection, the prevalence rate was not significantly higher among subjects with tattoos compared to those without tattoos. Although this might be primarily attributed to the small number of studies for the evaluation, several other elements must be considered. First, all the involved studies used screening tests for the diagnosis of syphilis infection. With these non-treponemal tests with high sensitivity [33–35], false-positive cases should be ruled out through confirmatory treponemal tests such as the fluorescent treponemal antibody-absorbed test or *Treponema pallidum* particle agglutination test [25, 33–35]. Second, the characteristic cutaneous manifestations of syphilis may lead to earlier recognition and initiation of interventions that can provide cure and thus cause negative screening test results [33, 34].

Our results raise other possibilities that could lead to an elevated incidence of TTDs in the tattooed population. Drews et al. [36] investigated behavioral differences in tattooed and non-tattooed college students using self-evaluation questionnaires. The tattooed male students' responses showed increased incidence of participation in risky behaviors, presence of more sexual partners, and higher arrest rates. The responses of tattooed females revealed an increased incidence of drug use and body piercings. These behaviors may also have been associated with the increased prevalence of TTDs.

From the perspective of the intrinsic properties of observational studies, this study has several limitations. First, the heterogeneity of the included meta-analyzed studies was considerably high. Second, we did not evaluate other databases (e.g., language-restricted and gray literature), which could have enabled us to access further epidemiological information. In addition, too few studies regarding syphilis in subjects with and without tattoos were available for the meta-analysis. Moreover, other behavioral factors (e.g., multiple sex partners), which are more common in tattooed subjects, might have been confounding factors and led to an overestimation of the effect of tattooing in TTD prevalence. Establishing a temporal relationship between having a tattoo and the morbidity of TTDs is also essential; however, we could not clarify this relationship owing to the lack of information in the included studies. Nevertheless, our study has strengths in that it presents a comprehensive review of a large number of studies covering various TTDs with a consistent methodology, and comprises and summarizes updated studies on the relationship between having tattoos and TTDs.

In conclusion, this study suggests that TTDs are more prevalent in people with tattoos than in those without tattoos. Apart from the hazardous effects of the tattoo materials themselves, the unhygienic conditions in which the procedures are performed may be associated with the spread of TTDs. Our study results support the idea that having a tattoo could be a risk factor for TTDs.

## Supporting information

**S1 File. Search strategies for database.** (DOCX)

**S1** Table. Characteristics and main findings of the included studies. (DOCX)

**S2** Table. Target diseases and related findings of the included studies. (DOCX)

S3 Table. Quality assessment of analytical studies that used the adapted Newcastle-Ottawa scale for cross-sectional studies. (DOCX)

**S1 Checklist. PRISMA 2009 checklist.** (DOC)

## **Author Contributions**

Conceptualization: Joung Soo Kim, Mi Youn Park, Eung Ho Choi.

**Data curation:** Sung Ha Lim, Solam Lee, Young Bin Lee, Chung Hyeok Lee, Jong Won Lee, Sang-Hoon Lee, Ju Yeong Lee.

Formal analysis: Sung Ha Lim, Solam Lee.

Funding acquisition: Eung Ho Choi.

Investigation: Sung Ha Lim, Solam Lee.

Methodology: Solam Lee, Sang Baek Koh.

Project administration: Eung Ho Choi.

Resources: Sung Ha Lim.

Software: Sung Ha Lim, Solam Lee.

Supervision: Eung Ho Choi.

Validation: Joung Soo Kim, Mi Youn Park, Sang Baek Koh, Eung Ho Choi.

Visualization: Sung Ha Lim, Solam Lee.

Writing - original draft: Sung Ha Lim, Solam Lee.

Writing - review & editing: Joung Soo Kim, Mi Youn Park, Eung Ho Choi.

### References

- Doss K, Ebesu Hubbard AS. The communicative value of tattoos: The role of public self-consciousness on tattoo visibility. Commun Res Rep. 2009; 26(1):62–74. <u>https://doi.org/10.1080/08824090802</u> 637072.
- Silver E, VanEseltine M, Silver SJ. Tattoo acquisition: A prospective longitudinal study of adolescents. Deviant Behav. 2009; 30(6):511–38. https://doi.org/10.1080/01639620802467771.
- Kluger N, Seite S, Taieb C. The prevalence of tattooing and motivations in five major countries over the world. J Eur Acad Dermatol Venereol. 2019; 33(12):e484–e6. https://doi.org/10.1111/jdv.15808 PMID: 31310367.
- 4. Laumann AE, Derick AJ. Tattoos and body piercings in the United States: a national data set. J Am Acad Dermatol. 2006; 55(3):413–21. https://doi.org/10.1016/j.jaad.2006.03.026 PMID: 16908345.
- Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996; 334(26):1685–90. <u>https://doi.org/10.1056/NEJM199606273342601</u> PMID: 8637512.
- Schmidt PJ. Syphilis, a disease of direct transfusion. Transfusion. 2001; 41(8):1069–71. <a href="https://doi.org/10.1046/j.1537-2995.2001.41081069.x">https://doi.org/10.1046/j.1537-2995.2001.41081069.x</a> PMID: 11493741.
- Centers for Disease Control and Prevention. Surveillance for Viral Hepatitis–United States, 2016. April 16, 2018. Available: <u>https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm</u>. Accessed July 7 2020.
- Centers for Disease Control and Prevention. HIV Surveillance Report, 2018 (Updated); vol. 31. May 2020. Available: http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html. Accessed July 7 2020.
- Alvarado-Esquivel C, Sablon E, Martinez-Garcia S, Estrada-Martinez S. Hepatitis virus and HIV infections in inmates of a state correctional facility in Mexico. Epidemiol Infect. 2005; 133(4):679–85. <a href="https://doi.org/10.1017/s0950268805003961">https://doi.org/10.1017/s0950268805003961</a> PMID: 16050514.
- Coppola RC, Masia G, Pradat P, Trepo C, Carboni G, Argiolas F, et al. Impact of hepatitis C virus infection on healthy subjects on an Italian island. J Viral Hepat. 2000; 7(2):130–7. <a href="https://doi.org/10.1046/j.1365-2893.2000.00199.x">https://doi.org/10.1046/j.1365-2893.2000.00199.x</a> PMID: 10760043.
- Matos SB, Jesus AL, Pedroza KC, Sodre HR, Ferreira TL, Lima FW. Prevalence of serological markers and risk factors for bloodborne pathogens in Salvador, Bahia state, Brazil. Epidemiol Infect. 2013; 141 (1):181–7. https://doi.org/10.1017/S0950268812000386 PMID: 22417705.

- Bhate P, Saraf N, Parikh P, Ingle M, Phadke A, Sawant P. Cross sectional study of prevalence and risk factors of hepatitis B and hepatitis C infection in a rural village of India. Arq Gastroenterol. 2015; 52 (4):321–4. https://doi.org/10.1590/S0004-28032015000400013 PMID: 26840475.
- de Nishioka SA, Gyorkos TW, Joseph L, Collet JP, MacLean JD. Tattooing and transfusion-transmitted diseases in Brazil: a hospital-based cross-sectional matched study. Eur J Epidemiol. 2003; 18(5):441– 9. https://doi.org/10.1023/a:1024277918543 PMID: 12889691.
- Myo K, San San O, Oo KM, Shimono K, Koide N, Okada S. Prevalence and factors associated with hepatitis C virus infection among Myanmar blood donors. Acta Med Okayama. 2010; 64(5):317–21. https:// doi.org/10.18926/AMO/40507 PMID: 20975765.
- Shittu AO, Olawumi HO, Issa BA, Nwabuisi C, Durotoye IA, Yussuf AD, et al. Risk factors and seroprevalence of hepatitis B surface antigen among blood donors in University of Ilorin Teaching Hospital, Ilorin, Nigeria. East Afr Med J. 2014; 91(2):57–61. PMID: 26859021.
- Mendez-Sanchez N, Motola-Kuba D, Zamora-Valdes D, Sanchez-Lara K, Ponciano-Rodriguez G, Uribe-Ramos MH, et al. Risk factors and prevalence of hepatitis virus B and C serum markers among nurses at a tertiary-care hospital in Mexico City, Mexico: a descriptive study. Ann Hepatol. 2006; 5 (4):276–80. PMID: 17151581.
- Khodadost M, Maajani K, Arabsalmani M, Mahdavi N, Tabrizi R, Alavian SM. Is tattooing a risk factor for hepatitis c transmission?: An updated systematic review and meta-analysis. Hepat Mon. 2017; 17(9): e14308. https://doi.org/10.5812/hepatmon.14308.
- Jafari S, Buxton JA, Afshar K, Copes R, Baharlou S. Tattooing and risk of hepatitis B: a systematic review and meta-analysis. Can J Public Health. 2012; 103(3):207–12. <u>https://doi.org/10.1007/ bf03403814 PMID: 22905640</u>.
- Jafari S, Copes R, Baharlou S, Etminan M, Buxton J. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010; 14(11):e928–40. <u>https://doi.org/10.1016/j.ijid.2010.03.019</u> PMID: 20678951.
- Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, et al. Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J Epidemiol Community Health. 2008; 62 (4):305–13. https://doi.org/10.1136/jech.2006.051599 PMID: 18339822.
- Ho PJ, Gernaat SAM, Hartman M, Verkooijen HM. Health-related quality of life in Asian patients with breast cancer: a systematic review. BMJ Open. 2018; 8(4):e020512. <u>https://doi.org/10.1136/bmjopen-2017-020512</u> PMID: 29678980.
- 22. Rahimi J, Gholami J, Amin-Esmaeili M, Fotouhi A, Rafiemanesh H, Shadloo B, et al. HIV prevalence among people who inject drugs (PWID) and related factors in Iran: a systematic review, meta-analysis and trend analysis. Addiction. 2020; 115(4):605–22. https://doi.org/10.1111/add.14853 PMID: 31631425.
- Dienstag JL. Acute viral hepatitis. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL et al., editors. Harrison's Principles of Internal Medicine, 20e. New York, NY: McGraw-Hill Education; 2018.
- Fauci AS, Folkers GK, Lane HC. Human immunodeficiency virus disease: AIDS and related disorders. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL et al., editors. Harrison's Principles of Internal Medicine, 20e. New York, NY: McGraw-Hill Education; 2018.
- Lukehart SA. Syphilis. In: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL et al., editors. Harrison's Principles of Internal Medicine, 20e. New York, NY: McGraw-Hill Education; 2018.
- Trickey A, Fraser H, Lim AG, Peacock A, Colledge S, Walker JG, et al. The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019; 4(6):435–44. https://doi.org/10.1016/S2468-1253(19)30085-8 PMID: 30981685.
- Long J, Allwright S, Barry J, Reynolds SR, Thornton L, Bradley F, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in entrants to Irish prisons: a national cross sectional survey. BMJ. 2001; 323(7323):1209–13. https://doi.org/10.1136/bmj.323.7323.1209 PMID: 11719410.
- Adjei AA, Armah HB, Gbagbo F, Ampofo WK, Boamah I, Adu-Gyamfi C, et al. Correlates of HIV, HBV, HCV and syphilis infections among prison inmates and officers in Ghana: A national multicenter study. BMC Infect Dis. 2008; 8(33. https://doi.org/10.1186/1471-2334-8-33 PMID: 18328097.
- Calzavara L, Ramuscak N, Burchell AN, Swantee C, Myers T, Ford P, et al. Prevalence of HIV and hepatitis C virus infections among inmates of Ontario remand facilities. CMAJ. 2007; 177(3):257–61. https://doi.org/10.1503/cmaj.060416 PMID: 17664449.
- Larney S. Does opioid substitution treatment in prisons reduce injecting-related HIV risk behaviours? A systematic review. Addiction. 2010; 105(2):216–23. https://doi.org/10.1111/j.1360-0443.2009.02826.x PMID: 20078480.
- Gahrton C, Westman G, Lindahl K, Ohrn F, Dalgard O, Lidman C, et al. Prevalence of viremic hepatitis C, hepatitis B, and HIV infection, and vaccination status among prisoners in Stockholm county. BMC Infect Dis. 2019; 19(1):955. https://doi.org/10.1186/s12879-019-4581-3 PMID: 31706284.

- World Health Organization. Global Hepatitis Report 2017. Geneva, Switzerland: World Health Organization; 2017.
- Calonge N, U. S. Preventive Services Task Force. Screening for syphilis infection: recommendation statement. Ann Fam Med. 2004; 2(4):362–5. https://doi.org/10.1370/afm.215 PMID: 15335137.
- Golden MR, Marra CM, Holmes KK. Update on syphilis: resurgence of an old problem. JAMA. 2003; 290(11):1510–4. https://doi.org/10.1001/jama.290.11.1510 PMID: 13129993.
- Cantor AG, Pappas M, Daeges M, Nelson HD. Screening for syphilis: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016; 315(21):2328–37. <u>https://doi.org/10.1001/jama.2016.4114 PMID: 27272584</u>.
- Drews DR, Allison CK, Probst JR. Behavioral and self-concept differences in tattooed and nontattooed college students. Psychol Rep. 2000; 86(2):475–81. <u>https://doi.org/10.2466/pr0.2000.86.2.475</u> PMID: 10840898.